Who is sponsoring NCT06954636?

NCT06954636 is sponsored by Sied Kebir.

What drugs are being tested in NCT06954636?

Interventions in NCT06954636: olfactory testing (threshold and identification test).

What condition does NCT06954636 study?

NCT06954636 studies Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adult.

Is NCT06954636 still recruiting?

NCT06954636 is currently recruiting now. Last updated 8 July 2025.

Last reviewed 2025-07-08 · How we verify

NCT06954636: OLFGBM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study

Recruiting now Last updated 8 July 2025

What this trial tests

trial testing olfactory testing (threshold and identification test) in Glioblastoma Multiforme, Adult in 128 participants. Currently enrolling.

Timeline

3 May 2023

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Sied Kebir
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	128
Start date	3 May 2023
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	2 locations across Germany

Drugs / interventions tested

olfactory testing (threshold and identification test)

Conditions studied

Glioblastoma Multiforme, Adult — all drugs for Glioblastoma Multiforme, Adult →
Glioblastoma or Gliosarcoma — all drugs for Glioblastoma or Gliosarcoma →
Glioblastoma, Adult — all drugs for Glioblastoma, Adult →

Sponsor

Sied Kebir

Who can join

18 and older, any sex, with Glioblastoma Multiforme, Adult or Glioblastoma or Gliosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Decoding glioblastoma survival: unraveling the prognostic potential of olfactory function in a prospective observational study.
Oster C, Matyar A, Schmidt T, Hummel T, et al · · 2025 · PMID 40708059 · DOI 10.1186/s42466-025-00410-2

Verify or expand the search:

Other recruiting trials for Glioblastoma Multiforme, Adult

Currently open trials in the same condition.

NCT05653622 — Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operate · Phase 2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
NCT05720078 — UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) · NA · recruiting
NCT05052957 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) · Phase 2 · recruiting

Other Sied Kebir trials

Trials by the same sponsor.

NCT07120620 — PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06954636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sied Kebir
Last refreshed: 8 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06954636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing